A Study to Evaluate How Apitegromab Works in Subjects Who Are Less Than 2 Years Old and Have Spinal Muscular Atrophy
Trial details
- Registry ID
- NCT07047144
- Phase
- Phase 2
The FDA approved Risdiplam (Evrysdi) on 7 Aug 2020.
Drug identity checked against registry records
Also recorded as Evrysdi
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| A Study to Evaluate How Apitegromab Works in Subjects Who Are Less Than 2 Years Old and Have Spinal Muscular AtrophyNCT07047144 | Scholar Rock, Inc. | Phase 2 | Recruiting | 2028-11Estimated |
| Date as reported | Drug / company | Event | Condition | Evidence |
|---|---|---|---|---|
| 2020-08-07Day | Risdiplam | FDA original application approvalFDA approval decision | Not specified | Open original sourceRead source excerpt{"application_number": "NDA213535", "applicant_as_listed_by_fda": "GENENTECH INC", "brand_names": ["EVRYSDI"], "active_ingredients": ["RISDIPLAM"], "submission_type": "ORIG", "submission_number": "1", "submission_status": "AP", "submission_status_date": "20200807", "matched_on": "drug name equals FDA sole active ingredient"} First seen: 06 Oct 2026 · Evidence last checked: 06 Oct 2026 |